The trial is evaluating the safety and tolerability when dosing patients with a whole plant extract.
Secondary outcomes include pharmacokinetics and the effects on pain, mood, sleep and opioid use over the duration of the trail.
No serious adverse events from dosing patients have been reported to date.
Dosing is expected to be completed by April 2020 with the final report to be provided by mid-2020.
Trial being done with Emerald Clinics Ltd (ASX:EMD)
Zelira’s managing director Dr Richard Hopkins said: “We are delighted to have achieved full enrolment, which represents a major milestone for the trial.
“We’re also pleased for the opportunity to expand our partnership with Emerald Clinics by bringing them on as a second site.
“We have been impressed by their ability to complement the efforts of the St Vincent team by rapidly screening and enrolling eligible patients into trial.”
Recent placement secures $4.6 million
Zelira recently accepted applications from overseas investors for an additional 1.08 million shares as part of a share placement.
Following the acceptance of oversubscriptions, the placement’s total size increased to $4.64 million.
The funds will be used to accelerate Zelira’s plans to launch multiple products into global markets in 2020 and to advance its clinical programs, including its Insomnia and Opioid Sparing trials, which are due to read-out in the first half of this year.
A global therapeutic medicinal cannabis company
Zelira is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest-growing cannabis markets.
The company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020.
It is currently undertaking:
- Human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA; and
- Pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.